LiverLearning®

2018 Transplant Hepatology Board Review Course

4.83 (18 votes)

Recorded On: 08/19/2018

This course will help prepare physicians for the American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) certification and maintenance of certification (MOC) exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint. High yield clinical topics will be presented by leaders in the field of hepatology and transplant medicine. Designed for ABIM/ABP Transplant Hepatology exam preparation, the course also provides a comprehensive review of up-to-date management of liver transplant patients.

Online Course Pricing:

  • Member — $325
  • Trainee and Associate Member — $185
  • Nonmember — $540
  • Nonmember Trainee / Associate — $235
  • Industry — $775

Core Competencies

  • Patient care and Procedural Skills
  • Medical knowledge
  • Practice-based learning and improvement
  • Patient-centered care
  • Evidence-based practice
  • Quality improvement
  • Values/Ethics for inter-professional practice

Program Chairs:

  • K. Gautham Reddy, MD, FAASLD
  • Oren K. Fix, MD, MSc, FAASLD
  • Laura M. Kulik, MD

Components

29 online interactive recorded sessions, 20-30 minutes in length
Post-activity quiz for each session

Release Date: September 14, 2018
Expiration Date: September 13, 2020

Copyright: All faculty in this activity have given their permission for publication OR ©2018 AASLD

K. Gautham Reddy (Moderator)

Oren K. Fix (Moderator)

Laura M. Kulik (Moderator)

Michael R. Lucey

Julie Heimbach

Michael R. Charlton

Marina G. Silveira

Jennifer C. Lai

Dr. Lai is a transplant hepatologist, on faculty at the University of California, San Francisco.  Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation.  Her primary research focuses on integrating core geriatric principles, such as frailty and physical function, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients.  She is the founder and principal investigator of the Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes.  For her work, she has been named a Beeson Scholar in Aging Research by the National Institute on Aging and a Top 40 Under 40 Leader by the San Francisco Business Times.

Philip Rosenthal

Michael F. Chang

Josh Levitsky

Robert J. Fontana

Jacquelyn F. Fleckenstein

Steven L. Flamm

Scott W. Biggins

Carl L. Berg

Sandy Feng

Norah A. Terrault

Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

 

 

Peter Chin-Hong

Michael D. Leise

Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

Mark W. Russo

Philip Rosenthal

Andrew I. Aronsohn

Lisa VanWagner

Dr. Lisa VanWagner is an Assistant Professor of Medicine and Preventive Medicine in the Division Gastroenterology & Hepatology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.  She is board certified in Transplant Hepatology.  Her laboratory utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease risk prediction, prevention and treatment approaches in patients with chronic liver disease.  Her research group developed the first simple scoring model (CAR-OLT score) — accessible via web or smartphone apps — which enables healthcare providers, caregivers and patients to estimate 1-year risk for cardiovascular complications after liver transplantation.

Key:

Complete
Failed
Available
Locked
Session I
Introduction
Open to view video.
Open to view video.
Liver Transplantation for Cholangiocarcinoma and Other Rare Tumors
Open to view video.
Open to view video.
Perioperative Complications
Open to view video.
Open to view video.
Liver Transplantation for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
Open to view video.
Open to view video.
Cholestatic and Autoimmune Liver Diseases
Open to view video.
Open to view video.
Nutritional Support in the Perioperative Setting Nutritional Support in Patients with Cirrhosis
Open to view video.
Open to view video.
Breakout (Adult): Alcoholic Liver Disease
Open to view video.
Open to view video.
Metabolic and Genetic Diseases I
Open to view video.
Open to view video.
Metabolic and Genetic Diseases II
Open to view video.
Open to view video.
Transplant Immunology
Open to view video.
Open to view video.
Immunosuppression and Rejection
Open to view video.
Open to view video.
Session I Quiz
10 Questions
10 Questions
Session II
Drug-Induced Liver Disease and Acute Liver Failure
Open to view video.
Open to view video.
Liver Diseases of Pregnancy
Open to view video.
Open to view video.
Hepatitis C Virus Infection: Pre- and Post-Liver Transplantation
Open to view video.
Open to view video.
Portal Hypertension
Open to view video.
Open to view video.
Selection and Evaluation for Transplantation
Open to view video.
Open to view video.
Donor Selection
Open to view video.
Open to view video.
Management of Hepatitis B and D in the Transplant Setting
Open to view video.
Open to view video.
Surgical Options and Complications Specific to Graft and Donor Types and Living Donors
Open to view video.
Open to view video.
Session II Quiz
8 Questions
8 Questions
Session III
Introduction
Open to view video.
Open to view video.
HCC and Post-Transplant Malignancy
Open to view video.
Open to view video.
Post Liver Transplant Infectious Complications
Open to view video.
Open to view video.
Recurrence of Disease After Liver Transplantation
Open to view video.
Open to view video.
Long Term Complications Post Liver Transplant
Open to view video.
Open to view video.
Breakout: Pediatric Topics
Open to view video.
Open to view video.
Potpourri
Open to view video.
Open to view video.
Ethics and Liver Transplantation
Open to view video.
Open to view video.
Statistics for the Boards
Open to view video.
Open to view video.
Wrap Up
Open to view video.
Open to view video.
Session III Quiz
12 Questions
12 Questions
Credits, Certificates, & Evaluation
CME Credits
Up to 11.50 medical credits available  |  Certificate available
Up to 11.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
MOC Points
Up to 11.50 medical credits available  |  Certificate available
Up to 11.50 medical credits available  |  Certificate available
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.

Upon completion of this activity, learners will be able to: 

  • Discuss the diagnosis, natural history, and therapies for liver diseases leading to liver transplantation;
  • Discuss the management of patients awaiting liver transplantation;
  • Discuss the immediate post-operative and long-term management of liver transplant recipients;
  • Discuss current organ allocation policy and its effects on selecting potential liver transplant recipients.


  • Hepatologists
  • Fellows/ Trainees

Satisfactory completion 

Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.   

CME 

Accreditation Statement The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation AASLD designates this enduring activity for a maximum of 11.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Maintenance of Certification

American Board of Internal Medicine (ABIM) MOC Statement 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pediatrics (ABP) MOC Statement

“Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 11.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.”

MOC Points Process

Physicians seeking MOC points must complete the CME evaluation in addition to viewing all of the presentation(s) and successfully passing the post-test(s) for each module with a score of 70% or better. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month.


DISCLOSURE OF CONFLICTS OF INTEREST

AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

The organizers and faculty have reported the following disclosures:

Andrew I. Aronsohn, MD
Faculty
Nothing to Disclose

Carl L. Berg, MD, FAASLD
Faculty Scientific
Consulting: Dova Pharnaceuticals, Grifols

Scott W. Biggins, MD, MAS, FAASLD
Faculty
Nothing to Disclose

Michael F. Chang, MD, MSc
Faculty
Nothing to Disclose

Michael R. Charlton, MD, FRCP
Faculty
Grant/Research Support: Intercept, GIlead Sciences, Merck, Janssen, AbbVie, Novartis Scientific
Consulting: Gilead Sciences

Peter Chin-Hong, MD
Faculty
Grants/Research Support: Karius

Sandy Feng, MD, PhD
Faculty
Stock/Stock Options: Abbott, Charles River Labs, Eli Lily, Express Scripts, Glaxo-Smith Klein, Medco, Merck, Pfizer, Hospira, Amgen, Johnson & Johnson, Stryker
Advisory Committees and/or Review Panels: Juno Therapeutics, Inc., American Journal of Transplantation, Immune Tolderance Network, OPTN/UNOS, The New England Journal of Medicine
Grants/Research Support: Novartis, Quark

Oren K. Fix, MD, MSc, FAASLD
Faculty
Nothing to Disclose

Steven L. Flamm, MD
Faculty
Nothing to Disclose

Jacquelyn F. Fleckenstein, MD, FAASLD
Faculty
Nothing to Disclose

Robert J. Fontana, MD, FAASLD
Faculty
Scientific Consulting: Alynam Pharmaceuticals
Grants/Research Support: BMS, Gilead, Abbvie

Julie Heimbach, MD, FAASLD
Faculty
Nothing to Disclose

Laura M. Kulik, MD
Faculty
Nothing to Disclose

Jennifer C. Lai, MD
Faculty
Scientific Consulting: Third Rock Ventures, LLC

Michael D. Leise, MD
Faculty
Nothing to Disclose

Josh Levitsky, MD, FAASLD
Faculty
Grants/Research Support: Novartis Scientific
Consulting: Novartis
Speakers Bureau: Gilead, Salix

Michael R. Lucey, MD, FAASLD 
Faculty
Grant/Research Support: Abbvie, Gilead, Pharmasoluions

Jorge A. Marrero, MD
Faculty
Scientific Consulting: Eisai, Grail, Exelis, Astra Zeneca

K. Gautham Reddy, MD, FAASLD
Faculty
Grants/Research Support: Merck, Intercept, Genfit
Scientific Consulting: Intercept
Speaker's Bureau: Intercept Dova Advisory
Committees and/or Review Panels: American College of Gastroenterology

Philip Rosenthal, MD, FAASLD
Faculty
Grants/Research Support: Gilead Scientific
Consulting: Gilead, Retrophin, Albireo

Mark W. Russo, MD, MPH, FAASLD
Faculty
Speakers Bureau: Gilead, Abbvie, Intercept, Salix

Marina G. Silveira, MD  
Faculty
Scientific Consulting: Conatus

Norah Terrault, MD, MPH, FAASLD
Faculty
Scientific Consulting: CME, CCO Hepatitis, Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc.
Advisory Committees or Review Panels: Merck, Intercept, Conatus, Dova
Grant/Research Support: AbbVie, Eisai, Gilead, BMS, Merck, Allergan, Biotest
Royalties: UpToDate

Lisa B. VanWagner, MD, MSc
Faculty
Grants/Research Support: Advanced MR Analytics (AMRA) Medical

Maintenance of Certification Committee

Oren K. Fix, MD, MSc, FAASLD
Chair
Nothing to disclose

Mark W. Russo, MD, MPH, FAASLD
Vice-Chair
Commercial Speaker's Bureau: Gilead, Abbvie,Intercept, Salix

Raymond T. Chung, MD, FAASLD
Board Liaison
Research Grants: Abbvie, Gilead Sciences, Boehringer Ingelheim

Curtis K. Argo, MD, MS, FAASLD
Member
Nothing to disclose

Steven K. Herrine, MD, FAASLD
Member
Research Grants: Gilead, BMS, Galectin, Interecept 
Leadership in related society: Board, Committee, Journal: ABIM - Chair, Transplant Hepatology Test Committee

Vandana Khungar, MD, MSc
Member
Nothing to disclose

Ayman A. Koteish, MD, FAASLD
Member
Nothing to disclose

Smruti R. Mohanty, MD, MS
Member
Advisory Board: Gilead science, Abbvie, Merck, Bristol Meyers Squib and Intercept
Leadership in related society: Board, Committee, Journal: Publications Committee, American College of Gastroenterology (2009- Present) Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology

Heather M. Patton, MD, FAASLD
Member
Nothing to disclose

K. Gautham Reddy, MD, FAASLD
Member
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept, Gilead
Research Grants: Merck Intercept Genfit
Commercial Speaker's Bureau: Intercept
Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of;

Grace L. Su, MD, FAASLD
Member
Company: Management Position

Ryan M. Taylor, MD
Member
Commercial Speaker's Bureau: Merck, Inc., Abbvie, Inc., Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb

Helen S. Te, MD, FAASLD
Member
Research Grants: Conatus Pharmaceuticals, Abbvie, Gilead Sciences
Advisory Board: Gilead Sciences,Intercept Pharmaceuticals

Debra Guss, RN, NP-C, ACRN
Associate
Nothing to disclose

Katie Duggan, BA
Staff Liaison
Nothing to disclose

Training and Workforce Committee

K. Gautham Reddy, MD, FAASLD
Chair
Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology;
Research Grants: Merck Intercept Genfit; Commercial Speaker's Bureau: Intercept Dova; Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept

Raymond T. Chung, MD, FAASLD
Board Liaison
Research Grants: BMS, Roche,Gilead Sciences, Abbvie, Boehringer Ingelheim

Christopher L. Bowlus, MD, FAASLD
Member
Research Grants: Gilead Biosciences, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Takeda Pharmaceuticals, NGM Biosciences, GlaxoSmithKline, Merck, BristolMyerSquibb, TARGET Pharmasolutions, Genkyotex, Allergan, JKB Taiwan Pharmaceuticals
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept Pharmaceuticals, GlaxoSmithKline, BristolMyersSquibb, Conatus, Patara, Eli Lilly

Michael F. Chang, MD, MSc, FAASLD
Member
Nothing to disclose

Hari S. Conjeevaram, MD, MS
Member
Nothing to disclose

Amy Feldman, MD
Member
Nothing to disclose

Aparna Goel, MD
Member
Nothing to disclose

Seth J. Karp, MD
Member
Nothing to disclose

Michael D. Leise, MD
Member
Nothing to disclose

Sylvia M. Lempit, MSN
Associate Member
Nothing to disclose

Michelle Long, MD
Member
Research Grants: Echosens

Ian R. Schreibman, MD
Member
Nothing to disclose

Jessica Davis, MD
Trainee
Nothing to disclose

Omar Y. Mousa, MD
Trainee
Nothing to disclose

Katie Duggan, BA
Staff Liaison
Nothing to disclose

Janeil Klett
Staff Liaison
Nothing to disclose